Failed Alzheimer’s Drug Trial Latest Setback for Treatment
Eli Lilly has halted two late-stage clinical trials for its experimental Alzheimer's treatment semagacestat, after it worsened patients' symptoms and increased their risk for skin cancer. Semagacestat was designed to block an enzyme in the brain that prompts the formation of amyloid plaque, the buildup of which is widely believed to cause Alzheimer's. However, an interim analysis of theÂ trials analyzing the drug'sÂ effectiveness in 2,600 patients showed that cognition and ability to execute daily tasks deteriorated more in participants takingÂ the drugÂ than in those taking a placebo.
- "Lilly Stops Two Alzheimer's Drug Trials" (Wilson, New York Times, 8/17).
- "Lilly Ends Work on Alzheimer Treatment" (Loftus/Rockoff, Wall Street Journal, 8/17).